Drug Trial Radar · NCT01335399
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
748
Actual
Start
Aug 4, 2011
Primary completion
Oct 1, 2019
Study completion Sep 3, 2021
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Apr 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)
Conditions
- Multiple Myeloma
Interventions
LenalidomideDrug
Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
DexamethasoneDrug
Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
DexamethasoneDrug
Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
DexamethasoneDrug
Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
DexamethasoneDrug
Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Elotuzumab (BMS-901608; HuLuc63)Biological
Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Elotuzumab (BMS-901608; HuLuc63)Biological
Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)
Locations
235 sites in 20 countries. Site status is shown where the registry gives one.
Local Institution - 1628
Birmingham, Alabama
Local Institution - 7619
Mobile, Alabama
Local Institution - 7618
Mobile, Alabama
Local Institution - 7617
Chandler, Arizona
Local Institution - 1644
Tucson, Arizona
Local Institution - 1618
Bakersfield, California
Local Institution - 1602
Berkeley, California
Local Institution - 1636
Corona, California
Local Institution - 1668
Corona, California
Local Institution - 1616
Greenbrae, California
Local Institution - 7609
Long Beach, California
Local Institution - 1660
Los Angeles, California
Local Institution - 1673
Orange, California
Local Institution - 1613
San Diego, California
Local Institution - 1621
New Haven, Connecticut
Local Institution - 1612
Washington D.C., District of Columbia
Local Institution - 1682
Boca Raton, Florida
Local Institution - 1617
Brooksville, Florida
Local Institution - 1648
Fort Myers, Florida
Local Institution - 7613
Hollywood, Florida
Local Institution - 1623
Jacksonville, Florida
Local Institution - 1625
New Port Richey, Florida
Local Institution - 1649
St. Petersburg, Florida
Local Institution - 1611
West Palm Beach, Florida
Local Institution - 1630
Atlanta, Georgia
Local Institution - 1684
Honolulu, Hawaii
Local Institution - 1607
Chicago, Illinois
Local Institution - 1635
Chicago, Illinois
Local Institution - 1632
Maywood, Illinois
Local Institution - 7606
Peoria, Illinois
Local Institution - 7610
Skokie, Illinois
Local Institution - 1603
Urbana, Illinois
Local Institution - 7616
Bloomington, Indiana
Local Institution - 7620
Indianapolis, Indiana
Local Institution - 1669
Indianapolis, Indiana
Local Institution - 1656
Mishawaka, Indiana
Local Institution - 1633
Iowa City, Iowa
Local Institution - 1674
Lexington, Kentucky
Local Institution - 1683
Louisville, Kentucky
Local Institution - 1646
Lafayette, Louisiana
Showing 40 of 235 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.